Patient guide · Respiratory & thoracic
Lung biopsy, CT-guided percutaneous or bronchoscopic sampling for definitive lung diagnosis.
Lung biopsy provides tissue for histology and molecular testing — the definitive step in lung nodule characterisation and lung cancer diagnosis. Modern options: CT-guided percutaneous, bronchoscopic (with EBUS or navigation), or thoracoscopic biopsy.
Why patients choose us
- 01
The right hands
A consultant interventional radiologist or thoracic physician who samples you and reports you — one clinician, one answer.
- 02
Full MDT wrap-around
Every biopsy sits inside a lung-cancer MDT — pathology, imaging, oncology and thoracic surgery on the same call.
- 03
Independent, and free
We are paid by no clinic, so the recommendation is impartial and costs you nothing.
Key facts
Lung biopsy at a glance.
The six things worth knowing before you scroll further — definition, the four sampling routes, and the molecular testing biopsy tissue enables.
- 01
Definition
Tissue sampling of a lung lesion for histology and molecular testing — the definitive step in lung nodule characterisation.
- 02
CT-guided percutaneous
Image-guided needle biopsy through the chest wall for peripheral lung lesions.
- 03
EBUS-TBNA
Endobronchial ultrasound with transbronchial needle aspiration — the workhorse for mediastinal and hilar nodes.
- 04
Navigation bronchoscopy
Electromagnetic or robotic navigation reaches peripheral lesions via the airways, without a chest-wall puncture.
- 05
Thoracoscopic (VATS) biopsy
Video-assisted thoracoscopic surgical biopsy for complex cases and interstitial lung disease.
- 06
Enables molecular and immuno testing
Tissue supports EGFR, ALK, ROS1, PD-L1 and other markers that decide targeted therapy and immunotherapy.
Preparation and pathway
From MDT to report — what happens, in order.
One MDT-backed pathway from first consultation to structured report — with a defined next step every time.
Phase 1 · Before your biopsy
Consultation, MDT, work-up
Phase 2 · On the day
Access, sampling, monitoring
Phase 3 · After
Observation and results
- 01
Before
Consultation and MDT review
A consultant reviews your CT, symptoms and comorbidities. The lung-cancer MDT confirms biopsy is the right step and the best route.
- 02
Before
Coagulation and pulmonary function
Clotting screen and lung-function tests — to confirm the lung reserve and clotting profile needed for a safe biopsy.
- 03
Before
Fast 4–6 hours pre-biopsy
Nil by mouth for four to six hours before the procedure. Regular medications and antiplatelets reviewed in advance.
- 04
On the day
IV access and monitoring
A cannula, oxygen saturations, blood pressure and ECG monitoring for the duration of the procedure and recovery.
- 05
On the day
CT-guided needle placement
Local anaesthetic, then image-guided needle passage into the lesion. Core or fine-needle samples taken under real-time imaging.
- 06
On the day
Sample sent to histopathology
Cores fixed, transported to pathology and processed for histology, immunohistochemistry and molecular panels.
- 07
After
2–4 hour post-procedure observation
Bed rest, serial observations and a post-procedure chest X-ray to exclude pneumothorax before discharge home.
Typical end-to-end: 1–2 weeks. Urgent cases: same week.
What it shows
What a lung biopsy can find.
The diagnoses lung biopsy is designed for — from the common lung cancers through granulomatous disease and interstitial lung disease, with the red-flag pathway called out separately.
-
Lung adenocarcinoma
The commonest non-small-cell lung cancer subtype — biopsy confirms histology and enables molecular testing.
-
Squamous cell carcinoma
Central or peripheral squamous NSCLC characterised on histology and immunohistochemistry.
-
Small cell lung cancer
Aggressive neuroendocrine tumour — biopsy confirmation triggers rapid oncology referral.
-
Neuroendocrine tumours
Carcinoid and other neuroendocrine tumours, graded on Ki-67 and mitotic count.
-
Sarcoidosis granulomas
Non-caseating granulomas on histology — often via EBUS-TBNA of mediastinal nodes.
-
Infection (TB, aspergillus)
Microbiological sampling for tuberculosis and fungal infection when imaging is atypical.
-
Interstitial lung disease (VATS)
Surgical lung biopsy provides the tissue volume needed to classify interstitial lung disease.
-
Red flag: post-biopsy pneumothorax needing drain — urgent intervention
A large or symptomatic pneumothorax needs same-visit chest drain and admission — do not delay.
Next steps
What happens after the biopsy.
The eight most common next steps — from MDT and molecular profiling through surgery, systemic therapy and structured surveillance.
-
Lung cancer MDT
Every confirmed cancer is discussed by pathology, imaging, oncology and thoracic surgery before treatment starts.
-
Molecular testing (EGFR, ALK, PD-L1)
EGFR, ALK, ROS1, BRAF and PD-L1 assays decide targeted therapy and immunotherapy eligibility.
-
Surgical resection (VATS lobectomy)
Video-assisted lobectomy for early-stage NSCLC — the curative option where fitness allows.
-
Chemotherapy / immunotherapy
Systemic therapy for advanced disease — often immunotherapy alone or combined with chemotherapy based on PD-L1.
-
Targeted therapy
Tyrosine kinase inhibitors for EGFR, ALK, ROS1 and other actionable mutations.
-
Radiotherapy
Stereotactic ablative radiotherapy (SABR) for early disease unfit for surgery, or radical/palliative RT for later stages.
-
Sarcoidosis treatment (steroids)
Oral corticosteroids for symptomatic or organ-threatening sarcoidosis, with respiratory follow-up.
-
Structured surveillance imaging
Interval CT surveillance for indeterminate nodules and post-treatment follow-up on defined intervals.
Red flags
When a lung biopsy needs urgent attention.
The nine situations that push a lung biopsy up the queue — and, in some cases, straight onto an emergency pathway.
-
Post-biopsy pneumothorax
The commonest complication — small pneumothoraces resolve; larger ones may need aspiration or a chest drain.
-
Haemothorax
Bleeding into the pleural space — uncommon but needs urgent chest imaging and, sometimes, drainage.
-
Massive haemoptysis
Significant blood in the sputum after biopsy — attend the clinic or A&E immediately.
-
Air embolism
Rare but serious — sudden neurological symptoms or cardiovascular collapse post-procedure demand emergency assessment.
-
Tumour seeding (rare)
A very small risk of tumour cells along the needle tract — considered in every planning decision.
-
Failed sampling
Non-diagnostic tissue — MDT may recommend repeat biopsy, a different route or direct surgical sampling.
-
Nodule progression on interval CT
A growing nodule on surveillance shifts an indeterminate lesion into a biopsy indication.
-
Suspected mesothelioma
Pleural thickening or effusion with an asbestos history — image-guided pleural biopsy or VATS is the pathway.
-
Post-procedure sepsis
Fever, rigors or persistent breathlessness after biopsy — same-day medical assessment.
Reading your report
A lung biopsy report can look intimidating. It isn’t.
Whatever the finding, the report keeps to the same four parts.
A quiet reminder
The report is written for your doctor, not for you — and that’s normal.
If you would like us to talk you through it before your follow-up, just ask.
- 01 Header
Indication and route
Your details, the reason for biopsy, and the route used — CT-guided, EBUS, navigation bronchoscopy or VATS.
- 02 Technique
Approach and sampling
Needle gauge, number of passes, tissue quality, sedation used and any peri-procedural events.
- 03 Findings
Histology and molecular results
Histological diagnosis, immunohistochemistry, and molecular results (EGFR, ALK, ROS1, PD-L1) as they arrive.
- 04 Impression
The conclusion — read this first
Diagnosis, stage where available, and the concrete next step — MDT outcome, treatment plan or surveillance interval.
Frequently asked
Everything we get asked about lung biopsy.
Quick answers on which route, pain, pneumothorax risk, how quickly results come back, and what happens if the biopsy is non-diagnostic.
-
What is a lung biopsy?
A lung biopsy is a procedure to sample tissue from a lung lesion or lymph node so a pathologist can make a definitive diagnosis. It is the step that turns an indeterminate scan finding into a precise diagnosis and a defined treatment plan.
-
Which route is right for me?
It depends on the lesion. CT-guided percutaneous biopsy suits peripheral nodules; EBUS-TBNA is the workhorse for mediastinal and hilar nodes; navigation bronchoscopy reaches peripheral lesions via the airways; thoracoscopic (VATS) biopsy is used when other routes are unsafe or when a larger sample is needed — commonly for interstitial lung disease. The MDT decides.
-
Is a lung biopsy painful?
Local anaesthetic numbs the chest wall for CT-guided biopsy, and light sedation is offered for bronchoscopic routes. Most patients describe pressure rather than pain. VATS biopsy is performed under general anaesthetic.
-
What is the risk of pneumothorax?
A small pneumothorax occurs in a meaningful minority of CT-guided lung biopsies. Most are small and settle without intervention; a smaller proportion need aspiration or a chest drain. The risk is assessed and consented in advance and monitored with a post-procedure chest X-ray.
-
How quickly will I get results?
Preliminary histology is usually available within a few working days; full molecular results (EGFR, ALK, ROS1, PD-L1) take one to two weeks. Findings are discussed at the lung-cancer MDT and communicated with a defined next step.
-
What happens if the biopsy is non-diagnostic?
The MDT reviews the samples, images and clinical picture. Options include repeat biopsy via a different route, direct surgical biopsy (VATS), or interval imaging where malignancy risk is low.
Sources
The guidance behind this guide.
- British Thoracic Society. Guideline for the investigation and management of pulmonary nodules.
- NICE. Lung cancer: diagnosis and management (NG122).
- European Respiratory Society. Statements and clinical guidelines.
- Royal College of Radiologists. Standards for interventional radiology.
Reviewed 2026-07-30 by Pulse Atlas Editorial Board, . Next review 2027-07-30. Estimated reading time 6 minutes.
Related tests
Looking for a different test?
-
CT lung assessment
High-resolution CT for lung nodule characterisation and staging.
Learn more -
EBUS
Endobronchial ultrasound for mediastinal and hilar node sampling.
Learn more -
Chest X-ray
First-line chest imaging for symptoms, screening and post-procedure.
Learn more -
All tests
Browse every test and procedure we arrange.
Learn more -
Asthma
Related condition guide.
Learn more -
COPD
Related condition guide.
Learn more -
Continuous Positive Airway Pressure
Related treatment option.
Learn more -
Complementary Alternative Medicine
Related treatment option.
Learn more
In practice, in London
The London pathway for lung biopsy
With lung biopsy, the London question is usually about report turnaround and the radiologist reading it — not whether the scan is available. The NHS route for lung biopsy is thorough, but the queue is real. Most patients we speak with have been told to expect anywhere from a handful of weeks to several months, depending on their local trust and how the referral is graded. Going private in London usually collapses that window to a matter of days — often the same week if the diary allows. It isn’t about jumping a queue so much as buying time back while you still have the flexibility to plan around it.
Once you’re in the private system for lung biopsy, the pace picks up noticeably. Consultant slots run to time, imaging is usually available in the same building or a short walk away, and the report comes back typed and detailed. It’s the coordination that tends to feel different — one person on the other end of the phone, not a switchboard. For lung biopsy specifically, the difference between a routine report and a sub-speciality read is where private care earns its keep.
Fit matters more than people expect. For lung biopsy, the right consultant depends on what you actually need — a second opinion, a definitive diagnosis, a bridge into treatment, or reassurance that nothing’s being missed. We match on that, not on who has the biggest brochure. If a test isn’t the right next step, we’ll say so before you book anything.